Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737887 | 0.98 | ALDH1A1 (0.41) | ALDH1A1MAPTMETAP2THRBATM | |
| SCHEMBL2770096 | 0.96 | MAPT (0.39) | ALDH1A1MAPTMETAP2L3MBTL1TDP1 | |
| SCHEMBL113236 | 0.92 | MAPT (0.41) | ALDH1A1MAPTL3MBTL1GAATSHR | |
| SCHEMBL6160281 | 0.87 | ALDH1A1 (0.39) | ALDH1A1MAPTMETAP2THRBATM | |
| Water SCHEMBL6160278 | 0.85 | ALDH1A1 (0.38) | ALDH1A1MAPTMETAP2THRBATM | |
| SCHEMBL28053511 | 0.85 | METAP2 (0.37) | ALDH1A1METAP2THRBATML3MBTL1 | |
| SCHEMBL15565165 | 0.84 | HPGD (0.40) | ALDH1A1METAP2THRBATML3MBTL1 | |
| SCHEMBL7639000 | 0.83 | GRM1 (0.40) | ALDH1A1MAPTL3MBTL1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL27995381 | 0.82 | GNAI3 (0.39) | MAPTEPHX1GAA | |
| SCHEMBL2517427 | 0.81 | ALDH1A1 (0.40) | ALDH1A1MAPTTHRBATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275032-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080275032-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080275032-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| WO-2008082725-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082725-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275032-A1 | Pyridazinone compounds | HAVCR2, PLPBP, CYP3A43 | ALDH1A1 1191/4885MAPT 2355/4885METAP2 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.